Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6021 as Mono Therapy or in Combination With Tislelizumab in Patients With Advanced Solid Tumors

NCT05120375 is registered in ClinicalTrials.gov with Bio-Thera Solutions as lead sponsor.

NCT NCT05120375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05120375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6021 as Mono Therapy or in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Lead sponsor
Bio-Thera Solutions
Phase
Phase 1
Overall status
Terminated
Start date
February 17, 2022
Completion date
April 7, 2023
Enrollment
5 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor